NCT00853372View on ClinicalTrials.gov

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 28, 2009

Primary Completion Date

August 8, 2011

Study Completion Date

June 25, 2019

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.

DRUG

Trebananib

Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY